Antibodies to human myeloperoxidase in glomerular immune deposits of systemic                 lupus erythematosus

Mannik, Mart; Merrill, Cynthia E.; Wener, Mark H.

doi:10.1191/096120300678828758

Cited by 14 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that anti-MPO antibodies have been reported in an inconsistent manner in SLE patients, which has been ascribed to detection methodology. The same study, however, reported that anti-MPO is deposited in the kidney glomerular basement membrane, the first study to do so [ 153 ].…”

Section: Mpo Usefulness As a Biomarker In Disease Statesmentioning

confidence: 99%

The many roles of myeloperoxidase: From inflammation and immunity to biomarkers, drug metabolism and drug discovery

Siraki

2021

Redox Biology

View full text Add to dashboard Cite

This review provides a practical guide to myeloperoxidase (MPO) and presents to the reader the diversity of its presence in biology. The review provides a historical background, from peroxidase activity to the discovery of MPO, to its role in disease and drug development. MPO is discussed in terms of its necessity, as specific individuals lack MPO expression. An underlying theme presented throughout brings up the question of the benefit and burden of MPO activity. Enzyme structure is discussed, including accurate masses and glycosylation sites. The catalytic cycle of MPO and its corresponding pathways are presented, with a discussion of the importance of the redox couples of the different states of MPO. Cell lines expressing MPO are discussed and practically summarized for the reader, and locations of MPO (primary and secondary) are provided. Useful methods of MPO detection are discussed, and how these can be used for studying disease processes are implied through the presentation of MPO as a biomarker. The presence of MPO in neutrophil extracellular traps is presented, and the activators of the former are provided. Lastly, the transition from drug metabolism to a target for drug development is where the review concludes.

show abstract

Section: Mpo Usefulness As a Biomarker In Disease Statesmentioning

confidence: 99%

The many roles of myeloperoxidase: From inflammation and immunity to biomarkers, drug metabolism and drug discovery

Siraki

2021

Redox Biology

View full text Add to dashboard Cite

show abstract

“…Lupus nephritis is characterized by glomerular immune deposition with the presence of immunoglobulins and complement components in kidney biopsy specimens. The etiology of this deposition is still unknown; however, antibodies specific to dsDNA, Sm, SSA, SSB, and C1q have been shown in glomerular despositions of proliferative Lupus nephritis [57][58][59] .…”

Section: Pathogenesis Of Lupus Nephritismentioning

confidence: 99%

Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy

Vuong

Hahn-Zoric

Lundberg

et al. 2010

Kidney International

View full text Add to dashboard Cite

The Fc-α receptor (FcαR/CD89) is involved in IgA complex formation and may affect the development of IgA nephropathy (IgAN). In this study, we tested the genetic variations of the CD89 gene in relation to disease susceptibility in IgAN and the expression of soluble CD89 (sCD89) in sera of patients with IgAN and in controls. There was a significant difference between the levels of sCD89-IgA complexes, measured by sandwich enzyme-linked immunosorbent assay (ELISA), in 177 patients with IgAN with and without disease progression at the time of first diagnosis. No such difference was found in 42 patients with other renal diseases. The patients with IgAN without disease progression had stable but high levels of sCD89 over 5-15 years of follow-up in contrast to stable but low levels of sCD89 in the disease progression group. Moreover, levels of sCD89 complexes were correlated with one of the five CD89 genetic variants in 212 patients with IgAN and 477 healthy Caucasians; the single-nucleotide polymorphism (SNP) rs11084377 was significantly associated with a lower expression of sCD89. However, no association between CD89 gene polymorphisms and susceptibility to IgAN was detected. Thus, we found an association between the levels of sCD89-IgA complexes in serum and the severity of IgAN, and a possible genetic component in regulating the production or expression of sCD89.

show abstract

“…In contrast to other autoimmune kidney diseases that are restricted to a specific autoAb (e.g., anti-collagen IV Abs in glomerular basement membrane), a vast array of autoAbs characterize LN patients with distinct subsets present in the kidney [58]. Indeed, the pioneering experiment conducted by Mannik et al from 23 post-mortem kidneys revealed the presence of a large panel of polyreactive Abs targeting dsDNA/chromatin/histone, Sm/RNP, SSA/B, C1q, and phospholipids [59]. Thanks to lupus-prone animal models and high-throughput technologies, the list of LN-associated Abs has been extended (Table 5), and this list included:…”

Section: Nephropathic Antibodies In Lnmentioning

confidence: 99%

Lupus Nephritis Risk Factors and Biomarkers: An Update

Renaudineau,

Brooks,

Belliere

2023

IJMS

View full text Add to dashboard Cite

Lupus nephritis (LN) represents the most severe organ manifestation of systemic lupus erythematosus (SLE) in terms of morbidity and mortality. To reduce these risks, tremendous efforts have been made in the last decade to characterize the different steps of the disease and to develop biomarkers in order to better (i) unravel the pre-SLE stage (e.g., anti-nuclear antibodies and interferon signature); (ii) more timely initiation of therapy by improving early and accurate LN diagnosis (e.g., pathologic classification was revised); (iii) monitor disease activity and therapeutic response (e.g., recommendation to re-biopsy, new urinary biomarkers); (iv) prevent disease flares (e.g., serologic and urinary biomarkers); (v) mitigate the deterioration in the renal function; and (vi) reduce side effects with new therapeutic guidelines and novel therapies. However, progress is poor in terms of improvement with early death attributed to active SLE or infections, while later deaths are related to the chronicity of the disease and the use of toxic therapies. Consequently, an individualized treat-to-target strategy is mandatory, and for that, there is an unmet need to develop a set of accurate biomarkers to be used as the standard of care and adapted to each stage of the disease.

show abstract

Antibodies to human myeloperoxidase in glomerular immune deposits of systemic lupus erythematosus

Cited by 14 publications

References 23 publications

The many roles of myeloperoxidase: From inflammation and immunity to biomarkers, drug metabolism and drug discovery

The many roles of myeloperoxidase: From inflammation and immunity to biomarkers, drug metabolism and drug discovery

Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy

Lupus Nephritis Risk Factors and Biomarkers: An Update

Contact Info

Product

Resources

About